Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarafenacin Phase 2 Study in Overactive Bladder
NCT01458197Phase 2Completed
- Sponsor
- Kwang Dong Pharmaceutical Co., Ltd.
- Start
- Sep 2011
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tarafenacin in overactive bladder (OAB), sponsored by Kwang Dong Pharmaceutical Co., Ltd.. Started Sep 2011; status: completed.
02
Drugs
tarafenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT01458197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01458197.